

1 **Additional file 1. Unadjusted and adjusted hazard ratios of virologic failure (n=**  
 2 **6264).**

3

|                                    | Univariate analysis |           |        | Multivariate analysis |           |        |
|------------------------------------|---------------------|-----------|--------|-----------------------|-----------|--------|
|                                    | cHR*                | 95% CI    | p      | aHR**                 | 95% CI    | p      |
| <b>VL group</b>                    |                     |           |        |                       |           |        |
| 6 months                           | 1                   |           | 0.257  | 1                     |           | 0.016  |
| 3 months                           | 1.10                | 0.93-1.29 |        | 0.78                  | 0.64-0.95 |        |
| <b>Sex</b>                         |                     |           |        |                       |           |        |
| Female                             | 1                   |           | 0.058  | 1                     |           | 0.767  |
| Male                               | 0.84                | 0.70-1.01 |        | 0.97                  | 0.80-1.18 |        |
| <b>Age</b> <sup>1</sup>            | 0.71                | 0.63-0.79 | <0.001 | 0.72                  | 0.64-0.81 | <0.001 |
| <b>CD4 count</b> <sup>2</sup>      | 0.90                | 0.85-0.95 | <0.001 | 0.91                  | 0.85-0.96 | 0.001  |
| <b>WHO stage</b>                   |                     |           |        |                       |           |        |
| I + II                             | 1                   |           | 0.001  | 1                     |           | 0.001  |
| III + IV                           | 1.50                | 1.19-1.89 |        | 1.57                  | 1.21-2.03 |        |
| <b>Clinic</b>                      |                     |           |        |                       |           |        |
| I                                  | 1                   |           | 0.28   | 1                     |           | 0.437  |
| II                                 | 0.96                | 0.78-1.19 |        | 0.92                  | 0.73-1.14 |        |
| III                                | 1.12                | 0.93-1.34 |        | 1.08                  | 0.90-1.30 |        |
| <b>Baseline NNRTI</b>              |                     |           |        |                       |           |        |
| Nevirapine                         | 1                   |           | 0.004  | 1                     |           | <0.001 |
| Efavirenz                          | 0.79                | 0.68-0.93 |        | 0.73                  | 0.61-0.87 |        |
| <b>ART initiation</b> <sup>3</sup> |                     |           |        |                       |           |        |
|                                    | 0.97                | 0.95-0.98 | <0.001 | 0.97                  | 0.95-0.98 | <0.001 |

4

5 \* cHR, crude hazard ratio

6 \*\* aHR, adjusted hazard ratio

7 \*\*\* PHA, p value for the global proportional-hazards assumption; VIF, range of

8 variance inflation factors

9 <sup>1</sup> per 10 years

10 <sup>2</sup> per 50 cells/ $\mu$ l

11 <sup>3</sup> Calendar time of ART initiation; per 90 days